Richard Knox

Since he joined NPR in 2000, Knox has covered a broad range of issues and events in public health, medicine, and science. His reports can be heard on NPR's Morning Edition, All Things Considered, Weekend Edition, Talk of the Nation, and newscasts.

Among other things, Knox's NPR reports have examined the impact of HIV/AIDS in Africa, North America, and the Caribbean; anthrax terrorism; smallpox and other bioterrorism preparedness issues; the rising cost of medical care; early detection of lung cancer; community caregiving; music and the brain; and the SARS epidemic.

Before joining NPR, Knox covered medicine and health for The Boston Globe. His award-winning 1995 articles on medical errors are considered landmarks in the national movement to prevent medical mistakes. Knox is a graduate of the University of Illinois and Columbia University. He has held yearlong fellowships at Stanford and Harvard Universities, and is the author of a 1993 book on Germany's health care system.

He and his wife Jean, an editor, live in Boston. They have two daughters.

This story begins 11 years ago. It was a time when many, if not most, experts said it was unthinkable to treat people with AIDS in developing countries using the triple-drug regimens that were routinely saving the lives of patients in wealthier countries.

A highly resistant form of a common bacterium recently popped up in two Rhode Island patients, only the 12th and 13th times it has been spotted in this country.

Most researchers currently believe that United Nations peacekeeping soldiers introduced cholera to Haiti in October of 2010.

After all, Haiti hadn't recorded cholera for as long as a century, Nepal had experienced a cholera epidemic in the months preceding the soldiers' arrival, and the Haitian and Nepalese cholera strains were found to be nearly identical.

Top AIDS scientists are scratching their heads about new data from the most famous HIV patient in the world — at least to people in the AIDS community.

Timothy Ray Brown, known as the Berlin patient, is thought to be the first patient ever to be cured of HIV infection.

China's first national survey of tuberculosis has produced some of the worst TB news in years.

Out of the million Chinese who develop TB every year, researchers say at least 110,000 get a form that's resistant to the mainstay drugs isoniazid and rifampin. Patients with such multidrug-resistant or MDR tuberculosis have to be treated for up to two years with expensive second-line drugs that are toxic and less effective.

In our recent poll on what it means to be sick in America, one ethnic group stands out as having special problems – Hispanic Americans.

The national survey, conducted by NPR with the Robert Wood Johnson Foundation and the Harvard School of Public Health, sheds new light on Hispanics' health issues. It runs counter to the widespread impression that African-Americans are worst-off when it comes to the cost and quality of health care.

A big study of a colon cancer test called flexible sigmoidoscopy may provide a good example of how a cheaper, easier-on-the-patient and possibly better technology isn't always the one American doctors choose to use.

In the lull between the Supreme Court arguments over the federal health overhaul law and the decision expected in June, we thought we'd ask Americans who actually use the health system quite a bit how they view the quality of care and its cost.

Most surveys don't break it down this way.

When the results came back, we found that people who have a serious medical condition or who've been in the hospital in the past year tended to have more concerns about costs and quality than people who aren't sick. No big surprise there.

U.S. government spending to fight HIV/AIDS in developing countries is also preventing death from other diseases, a new study finds.

Some experts worry the billions of dollars the United States spends to treat people with HIV in poor countries may crowd out prevention and treatment of other illnesses.